Phase 3 trial comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
The French explorer and Acadia's first historian Marc Lescarbot described Jerusalem artichokes as being "as big as turnips or truffles," suitable for eating and taste "like chards, but more pleasant." In 1629, the English herbalist and botanist John Parkinson wrote that the widely grown Jerusalem artichoke had become very common and cheap in London, so much so "that even the most vulgar begin to despise them." In contrast, when they had first arrived in England, the tubers had been "dainties for the Queen." Lewis and Clark ate the tubers, prepared by an indigenous woman, in modern-day North Dakota. They have also been called the "Canadian truffle".
==== Australia ==== In July 2000, the first location in Australia opened in Sydney. After a massive downturn in 2008, the remaining Australian Starbucks stores were sold to the Withers family in 2014, with the company planning a more restrained expansion. As of November 2022, there are 59 Starbucks stores in Australia; 23 in New South Wales, 19 in Queensland and 18 in Victoria. These stores are spread out across Sydney, Melbourne, Brisbane, the Gold Coast, the Sunshine Coast and Ballarat. Before the mass-closure of 61 of their 85 stores in 2008, there were also stores in Adelaide, Canberra, Hobart and Wollongong. However, there are plans to open a restaurant in Toowoomba while the first store in Perth, Western Australia opened on October 23, 2024, with another 11 planned to open by the end of 2025.
=== Temperature dependence === The Young's modulus of metals varies with the temperature and can be realized through the change in the interatomic bonding of the atoms, and hence its change is found to be dependent on the change in the work function of the metal. Although classically, this change is predicted through fitting and without a clear underlying mechanism (for example, the Watchman's formula), the Rahemi-Li model demonstrates how the change in the electron work function leads to change in the Young's modulus of metals and predicts this variation with calculable parameters, using the generalization of the Lennard-Jones potential to solids. In general, as the temperature increases, the Young's modulus decreases via
=== Development === The episode was written by executive producer John Carcieri, executive producer Jeff Fradley, and series creator Danny McBride, and directed by executive producer Jody Hill. This was Carcieri's 19th writing credit, Fradley's 13th writing credit, McBride's 28th writing credit, and Hill's 14th directing credit.
Sources: en.wikipedia.org
transuranic elements Also transuranium elements. The set of chemical elements with an atomic number greater than 92, i.e. occurring after uranium in the periodic table. None of the transuranic elements are stable in naturally occurring conditions.
== Stop codon recognition == The termination of translation is determined by the presence of a release factor recognizing a stop codon, which then catalyzes the release of the newly synthesized protein. There are three stop codon found within all domains of life: UGA, UAG, and UAA. Each stop codon starts with a uracil nucleotide followed by two purines (adenosine and guanine), which is essential for the molecular basis of stop codon recognition. The eRF1 protein is capable of recognizing all three stop codons, which means it must have a way to differentiate codons very efficiently. The three sites used for stop codon recognition are the YxxCxxxF, GTS loop and NIKS site. The main object of the highly specialized sites is to create extensive networks of hydrogen bonding crosslinking with the mRNA stop codon. The process is separated into two sections: recognizing the first nucleotide (uracil) and recognizing the second and third position nucleotides.
In 1886, Eugen Goldstein observed rays in gas discharges under low pressure that traveled away from the anode and through channels in a perforated cathode, opposite to the direction of negatively charged cathode rays (which travel from cathode to anode). Goldstein called these positively charged anode rays "Kanalstrahlen"; the standard translation of this term into English is "canal rays". Wilhelm Wien found that strong electric or magnetic fields deflected the canal rays and, in 1899, constructed a device with perpendicular electric and magnetic fields that separated the positive rays according to their charge-to-mass ratio (Q/m). Wien found that the charge-to-mass ratio depended on the nature of the gas in the discharge tube. English scientist J. J. Thomson later improved on the work of Wien by reducing the pressure to create the mass spectrograph.
Epistles 13–14 of the first part of the Epistles of Wisdom focus on Jesus, detailing his ministry, his crucifixion by the Jews, and his descent from the cross. According to these epistles, Hamza bin Ali took him down from the cross and allowed him to return to his family, with the aim of preparing people to preach his religion. The epistle titled "Excuses and Warnings" foretells that, as a sign of the end times, Messiah Jesus "the son of Joseph and Mary", will appear in Egypt. The Jews will seize control of Jerusalem and seek revenge on the inhabitants of both Jerusalem and Acre. Subsequently, Messiah Jesus will expel the Jews from Jerusalem, and Christians will dominate Muslims until the Day of Judgment, when the divine Al-Hakim bi-Amr Allah returns to judge humanity. The author of the epistle "The Report of the Jewish and Christians" (Khabar al-Yahud wal Nasara), part of first volume of the Epistles of Wisdom, appears to have been a Druze individual. The account itself identifies him as Hamza ibn Ali, a supporter of al-Hakim's divinity and the founder of the Druze faith. Hamza ibn Ali reportedly died after al-Hakim's disappearance in 1021. In the 18th century, the Orientalist Jean Michel de Venture de Paradis mentioned obtaining a manuscript discovered in a Druze village. This manuscript contained, among other things, a description of a dialogue between al-Hakim and leaders of the Christian and Jewish communities. Additionally, it included eight letters written by al-Hakim's lieutenant, Hamza ibn Ali, with the final one titled "The Report of the Jewish and Christians".
=== Interpretation of quantum mechanics === Jung influenced one philosophical interpretation (not the science) of quantum physics with the concept of synchronicity regarding some events as non-causal. That idea influenced the physicist Wolfgang Pauli (with whom, via a letter correspondence, Jung developed the notion of unus mundus in connection with the idea of nonlocality) and some other physicists.
Sources: en.wikipedia.org
After rail services were extended to Dover in 1844, the Western Docks were used as a terminal for the Golden Arrow and other cross-channel train services with its own railway station, Dover Marine, later renamed Dover Western Docks. At Dover Marine station an estimated 5 million troops departed for the trenches of World War I and nearly 1.5 million wounded soldiers returned. In 1920 the remains of the Unknown Warrior were landed prior to transportation to London and a ceremonial interment at Westminster Abbey. Dover Marine railway station closed in 1994, later to be redeveloped into Cruise Terminal One. The Western Docks area was also used from 1968 to the early 2000s for a cross-channel hovercraft service run by Hoverspeed. Hoverspeed also ran catamaran services until being declared bankrupt in 2005. Another catamaran service was run from 2004 until November 2008 by the single ship of SpeedFerries, SpeedOne, with up to five services daily to Boulogne-sur-Mer. The hoverport has now been demolished and redeveloped as a cargo handling facility.
==== Experimental observations ==== Graphene samples prepared on nickel films, and on both the silicon face and carbon face of silicon carbide, show the anomalous effect directly in electrical measurements. Graphitic layers on the carbon face of silicon carbide show a clear Dirac spectrum in angle-resolved photoemission experiments, and the effect is observed in cyclotron resonance and tunneling experiments.
low: hs-CRP level under 1.0 mg/L average: between 1.0 and 3.0 mg/L high: above 3.0 mg/L Normal levels increase with aging. Higher levels are found in late pregnant women, mild inflammation and viral infections (10–40 mg/L), active inflammation, bacterial infection (40–200 mg/L), severe bacterial infections and burns (>200 mg/L). CRP cut-off levels indicating bacterial from non-bacterial illness can vary due to co-morbidities such as malaria, HIV and malnutrition and the stage of disease presentation. In patients presenting to the emergency department with suspected sepsis, a CRP/albumin ratio of less than 32 has a negative predictive value of 89% for ruling out sepsis. CRP is a more sensitive and accurate reflection of the acute phase response than the ESR (erythrocyte sedimentation rate). ESR may be normal while CRP is elevated. CRP returns to normal more quickly than ESR in response to therapy.
In the 1950s, Har Gobind Khorana and co-workers developed a phosphodiester method where 3'-O-acetylnucleoside-5'-O-phosphate 2 (Scheme 3) was activated with N,N'-dicyclohexylcarbodiimide (DCC) or 4-toluenesulfonyl chloride (Ts-Cl). The activated species were reacted with a 5'-O-protected nucleoside 1 to give a protected dinucleoside monophosphate 3. Upon the removal of 3'-O-acetyl group using base-catalyzed hydrolysis, further chain elongation was carried out. Following this methodology, sets of tri- and tetradeoxyribonucleotides were synthesized and were enzymatically converted to longer oligonucleotides, which allowed elucidation of the genetic code. The major limitation of the phosphodiester method consisted in the formation of pyrophosphate oligomers and oligonucleotides branched at the internucleosidic phosphate. The method seems to be a step back from the more selective chemistry described earlier; however, at that time, most phosphate-protecting groups available now had not yet been introduced. The lack of the convenient protection strategy necessitated taking a retreat to a slower and less selective chemistry to achieve the ultimate goal of the study.
==== Co-evolutionary evidence ==== An independent molecular analysis trying to establish the dates when bat ectoparasites (bedbugs) evolved came to the conclusion that bedbugs similar to those known today (all major extant lineages, all of which feed primarily on bats) had already diversified and become established over 100 million years ago, suggesting that they initially all evolved on non-bat hosts and "bats were colonized several times independently, unless the evolutionary origin of bats has been grossly underestimated". No analysis has provided estimates for the age of the flea lineages associated with bats. The oldest known members of a different lineage of bat ectoparasites (bat flies), however, are from roughly 20 million years ago, well after the origin of bats. The bat-ectoparasitic earwig family Arixeniidae has no fossil record but is not believed to originate more than 23 million years ago.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the standard technique for purity and content. Mass spectrometry provides orthogonal confirmation of identity. The two are normally used together rather than in isolation.